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1. Introduction 
Tuberculosis (TB), caused by the intracellular bacterium, Mycobacterium tuberculosis (Mtb), 
has been a major health concern since it plagued ancient Egypt 5 thousand years ago. TB 
infects 9 million people every year, most of them children (especially in endemic areas), and 
it leads to approximately 2 million deaths annually (World Health Organization [WHO], 
2008; Kabra & Lodha, 2004; Marais & Pai, 2007). These numbers are expected to increase in 
the coming years because of (1) the AIDS pandemic—a high percentage of the patients with 
human immunodeficiency virus (HIV) are co-infected with Mtb, and (2) the emergence of 
drug-resistant strains of the TB organisms (Corbett et al., 2003; Raviglione, 2003; WHO, 
1994). This alarming increase in morbidity and mortality highlights the need to strengthen 
control measures. Accurate and rapid diagnosis is essential for controlling the disease, yet 
the traditional tests for TB produce results that are either inaccurate or take too long to be 
definitive. A fast and reliable diagnostic method that could differentiate between active and 
latent TB infection is lacking as well.  
The current routine diagnostic tests for TB: sputum smear microscopy, chest X-ray, Mtb 
culture, tuberculin skin test, acid-fast staining, and serological tests—all have their 
limitations. Sputum smear microscopy can produce false negative results, whereas the acid-
fast staining requires a large number of bacteria in the sputum to give an accurate reading; a 
chest X-ray alone is inconclusive; Mtb culture takes too long to produce a result; the 
tuberculin skin test lacks specificity and reliability; and serological tests, which use different 
TB antigens to detect Mtb infection, are fast but they lack the necessary sensitivity.  
The only available TB vaccine is the bacille Calmette Géurin (BCG) vaccine, which is uneven 
in its efficacy. Various reports have indicated variable levels of protection ranging from 0 
percent to 80 percent in different populations (Fine, 1995; Tuberculosis Research Centre 
[ICMR], 1999). Therefore, despite the fact that most people in developing countries are 
vaccinated with BCG at birth, TB is still a major public health problem. The prevalence of TB 
infection is reported as being as high as 40 percent worldwide, and the annual risk of 
infection is 2–4 percent worldwide (Anil, 1995). 
Clinically, TB has two forms: An active form and a latent form (which is asymptomatic and 
non-contagious). If undiagnosed and untreated, a patient with active pulmonary TB will 
transmit the infection to 10–15 people each year (WHO, 2006). However, active TB is also 
fueled by the vast reservoir of latent TB infections that become reactivated. 
Immunocompetent individuals latently infected with Mtb have a 10 percent lifetime risk of 
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developing active TB (Syblo, 1980; Harada, 2006). Data show that 5 percent of latently 
infected individuals will progress to active TB in the first 2 years after acquiring the 
infection, and an additional 5–10 percent of infected people will develop the active disease 
later in their lives (Comstock et al., 1974). This risk increases for people co-infected with 
HIV—especially children, for whom diagnosis of TB is even more challenging (Corbett et al., 
2004).  
If diagnosed, latent TB infected individuals can be cured with anti-tuberculosis treatment, 
which prevents progression to the active form of the disease. Because effective TB control 
can only be achieved with the accurate diagnosis and treatment of both active and latent 
infections, modern TB control programs require the identification of latent TB infection to 
the highest clinical standards. Accurate diagnosis and preventive treatment of latently 
infected individuals can substantially decrease the chance of development into active TB 
(Cohn, 2000). Delayed diagnosis, because of inaccuracy or the unavailability of diagnostic 
requirements—including the availability of rapid and accurate diagnostic methods—can 
preclude timely therapy, which may result in increasing morbidity and mortality, greater 
lung damage resulting in chronic disability, and higher health care costs (Kehinde et al., 
2005; WHO, 2009).  
The diagnosis dilemma for clinical TB continues to be a global issue. For pulmonary TB, it 
can be difficult to obtain robust respiratory specimens from the elderly, the young, and 
immuno-compromised patients. For those with extra-pulmonary TB, tissue biopsy is 
essential for histopathological and microbiological diagnosis (Bukhary & Alrajhi, 2004), yet 
techniques to obtain and examine biopsies are not available in all hospitals and may be 
associated with complications. A simple, noninvasive, rapid, and accurate method of 
diagnosis needs to be developed for successful treatment of both active and latent TB; with 
such a method, person-to person transmission of the disease would be greatly reduced, 
which would have a major impact on TB morbidity and mortality worldwide (Cambanis et 
al., 2007). 
1.1 Specimen collection 
For the detection of pulmonary and/or extrapulmonary TB, tests usually require sputum, 
gastric lavage, blood, urine, or other bodily fluids (such as cerebrospinal fluid, pleural, or 
ascetic fluid); in addition, tissue biopsy specimens are collected for the diagnosis of 
extrapulmonary TB. One of the objectives of developing TB biochemical markers and 
immunological assays is to replace the need for collecting tissue biopsy specimens from TB 
patients for diagnosis of the disease. Likewise, the development of immunochromatography 
tests (ICT), for which urine is used as a specimen, is an attempt to make diagnostic tests less 
invasive and costly, more rapid, and patient friendly. Up until now, regardless of which test 
is used, that test is usually accompanied by microbiological tests (smear microscopy and 
mycobacterial culture of sputum) to diagnose pulmonary TB and to determine the treatment 
be used. Sputum samples, after being collected, are decontaminated by using normal 
sodium hydroxide-N-acetyl-L-cystein (NaOH-NALC) and then sometimes centrifuged to 
get a better yield of the organisms (Kent & Kubica, 1985). Often three sputum samples are 
collected, including a “spot” specimen collected on the first day (first sputum); a morning 
(second sputum); and “spot” specimen (third sputum) collected on the second day. 
However, collecting adequate amount of sputum from patients is not always possible, 
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especially in children younger than 10 years old or in adults who cannot produce enough 
sputum. In situations like these, procedures to stimulate cough with an aerosol solution 
and/or bronchoalveolar or gastric lavage can be used (Capelozzi et al., 2011; Mohan et al., 
1995; Somu et al.,1995). 
2. Traditional TB diagnostic tests and their associated problems 
Traditional TB diagnosis usually requires high clinical presentation, laboratory materials, 
and methods for sputum smear microscopy (acid-fast bacilli), culture on solid and/or liquid 
media, chest radiography, and the tuberculin skin test. Tissue sampling is usually needed to 
confirm preliminary results in cases of extra-pulmonary TB. All of these tests have their 
respective shortcomings. 
2.1 Sputum smear microscopy  
Sputum-smear microscopy is 100 years old, but it is still the primary, easy to use, and 
affordable test for the confirmation of pulmonary TB at the lower level of health services. 
Acid-fast bacilli smear Ziehl-Neelsen (ZN) microscopy, which is prepared from 
unconcentrated sputum (direct smear), is the main laboratory tool supporting case 
detection. It is inexpensive and is relatively specific in settings where tuberculosis is 
endemic. However, direct smear microscopy can produce false-negative results, which have 
been observed in more than 30–50 percent of adult patients (Miorner et al., 1994; Daniel 
1990), particularly in high HIV-prevalent settings (Elliot et al., 1993; Frieden et al., 2003; 
American Thoracic Society Workshop, 1997), and 85–90 percent of infected children 
(Newton et al., 2008). The acid-fast bacilli false-negative result rate is attributable, in part, to 
the low sensitivity of the test, which requires more than 10,000 bacilli per milliliter of 
sputum for reliable detection (Perkins, 2000). Obtaining good sputum samples can be 
difficult, and the studious attention of trained and motivated technicians (who are not 
always available) is necessary.  
Many attempts have been made to improve and optimize the performance of smear 
microscopy, including with new technologies (Mase et al., 2007; Bonnet et al., 2007; Ramsay 
et al., 2009; Mabaera et al., 2007; Van Deun et al., 2004), such as fluorescence microscopy, 
which uses inexpensive light-emitting diodes (LED) as an alternative for conventional ZN 
microscopy. This substitution increases the sensitivity of the test and is easy to use, even in 
peripheral laboratories where culture facilities are not available (Hooja et al., 2011; Steingart 
et al., 2006a; Steingart et al., 2006b; Steingart et al., 2007; Van Deun et al., 2008; Trusov et al., 
2009; Minion et al., 2009; Bonnet et al., 2011). In fact, the World Health Organization (WHO) 
Strategic and Technical Advisory Group (STAG) for TB recommended that fluorescence 
microscopy be phased in as an alternative for ZN (WHO, 2009), because it can be used even 
in low-income, high TB burden settings. It has been reported that LED fluorescence 
microscopy, either alone or in combination with single-specimen tests, could increase 
considerably the identification of smear-positive cases (Cattamanchi et al., 2010).  
A wide variety of stains or fluorescence quenchers have been used with the LED 
fluorescence microscopy; however potassium permanganate at 0.5 percent in water is the 
stain most frequently used. Although potassium permanganate can produce very good 
results with the classical fluorescence microscopy systems (using mercury vapor lamps and 
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epifluorecence), the very dark background sometimes makes it difficult to focus. Methylene 
blue (Mblue) is an alternative to potassium permanganate, which yields comparable results 
(Van Deun et al., 2010).  
In an attempt to improve the performance of smear microscopy, sputum processing 
methods using household bleach (NaOCl), followed by a specimen concentration step (such 
as centrifuge or sedimentation, mentioned above), can be done in any laboratory setting 
before smear microscopy is used (Steingart et al., 2006; Angeby et al., 2004; Annam et al., 
2009). However, some reports indicate that NaOCl sedimentation did not improve the 
performance of LED fluorescence microscopy in the diagnosis of pulmonary TB at low 
levels of health service in resource-poor countries (Bonnet et al., 2011).  
Because the acid-fast bacilli smear is based on sputum, extra-pulmonary TB detection 
varies with the cytomorphology of inflammation at the site of infection, which is limited 
and may not exceed 40 percent (Nigussie et al., 2010; Gangane et al., 2008). The sputum 
smear microscopy test may also identify certain types of bacteria that are not Mtb, thus 
yielding a false-positive result for TB. The WHO estimates sputum smear microscopy only 
identifies 35 percent of patients with TB (Harris, 2004; Thornton et al., 1998). Furthermore, 
the 2010 WHO report indicated that in 2009, 43 percent of the 4.6 million reported new 
cases of pulmonary TB were diagnosed without microbiological confirmation (WHO, 
2010). The failure to confirm TB infection can delay initiation of the appropriate therapy to 
adequately treat cases, which could prevent the further spreading of the disease 
(Cambanis et al., 2007).  
2.2 Solid or liquid cultures 
Solid or liquid cultures are still seen as the gold standard for TB detection because they are 
sensitive to live Mtb in the sputum sample; they can also provide data on the likely 
effectiveness of certain chemotherapeutic agents against TB. However, there are serious 
drawbacks to this test, such as the time needed to obtain the result (3–8 weeks). Clinical and 
therapeutic decisions are often made before the culture results are available. However, few 
facilities in low-income settings use culture for the diagnosis of TB; for those facilities the 
main method of diagnosis is sputum microscopy with acid. When culture is used in these 
settings, the Löwenstein-Jensen solid, egg-based, and agar-based Middlebrook 7H10 media 
are the ones used to recover mycobacteria from clinical materials (Metchock et al., 1999; 
Murray et al., 1998); these can take weeks to show results.  
2.2.1 Advantages and disadvantages of cultures 
A number of manual and automated systems have been developed to reduce the detection 
time of mycobacteria in clinical specimens. Both the biphasic Septi-chek acid-fast bacilli 
(Becton Dickinson, Sparks, MD) and the MB-Redox (BiotestAG, Dreieich, Germany) are 
examples of the manual systems. Advances in technology have led to the development of 
the automated systems such as radiometric BACTEC 460TB (Becton Dickinson), the 
fluorometric BACTEC MB9000 and BACTECMGIT (Mycobacteria Growth Indicator 
Tube), 960 systems (Becton Dickinson), the carbon dioxide–sensing MB/BacT ALERT 3D 
System (Organon Teknika, Durham, NC), and the pressure-sensing ESP Culture System II 
(Trek Diagnostic Systems, Westlake, OH). Detection time and isolation of Mtb were 
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considerably improved (7–21 days) with the use of liquid media, such as the radiometric 
BACTEC 460 TB broth-based system. However, this procedure still requires trained 
technicians and special attention to safety issues regarding radioisotopes (Salfinger & 
Pfyffer, 1994; Laszlo et al., 1983). Another disadvantage of the BACTEC 460 TB system is 
the increased cost of radioactive waste disposal, an issue that encouraged manufacturers 
to develop a better alternative. The fully automated BACTEC Mycobacteril Growth 
Indicator Tube (MGIT) liquid medium system with early growth indicators (the BACTEC 
MGIT 960 system), is faster and more sensitive than both LJ and BACTEC 460 TB for 
testing the susceptibility of antituberculosis agents, and it is more effective in diagnosing 
the disease in smear-negative samples; this feature shows great potential to reduce the 
mortality rate from TB (Lu et al., 2002; Gérôme et al., 2009; Sinirtas et al., 2009; Morcillo et 
al., 2010).  
The BACTEC MGIT 960 system is a high-capacity, fully automated continuous-monitoring 
system, which can test up to 960 samples for the rapid detection of mycobacteria, making it 
suitable for those laboratories dealing with a large number of specimens (Somoskovi et al., 
2000; Hanna et al., 1999; Tortoli et al., 1999; Lee et al., 2003). In the determination of the early 
bactericidal activity in the clinical studies of new anti-tuberculosis agents, it has been found 
that the time of detection of MGIT 960 is better than colony-forming units of Mtb on solid 
media (Diacon et al., 2010).  
Although the WHO recently recommended the expanded use of liquid culture systems, 
such as MGIT, in resource-constrained settings (WHO, 2007), historically these systems have 
not been used because of the high cost of the tests and the culture contamination rates 
(Chihota et al., 2010). The relatively high contamination rates of the MGIT culture has been 
reported to range from 5.5 to 15 percent in high-income settings, and as high as 29.3 to 33 
percent in resource-constrained settings (Chien et al., 2000; Lee et al., 2003; Hanna et al., 
1999; Somoskvi et al., 2000; Chihota et al., 2010).  
2.2.2 New approaches to cultures 
Using simple and inexpensive monoclonal assays, such as the Capilia TB assay (a rapid and 
low-technology method), which uses monoclonal antibodies to detect a secreted 
mycobacterial protein (MPB64) during culturing (solid or liquid culture) allows it to 
differentiate Mtb from non-TB mycobacteria (Muyoyeta et al., 2010; Ngamlert et al., 2009). 
To shorten the time required for bacterial growth detection, Mtb can be isolated in both 
liquid- and solid-media cultures (Lu et al., 2002).  
Although automated systems such as BACTEC 460 TB, BACTEC 9000, and MGIT can be 
used to accelerate the growth of the bacteria, they can also produce inaccurate results 
(Daniel, 1987). Plus, it is not always possible to obtain bacteria in the sputum sample. False-
positives, which range from 0.1 percent to 65 percent because of laboratory contamination is 
another concern with the culture technique (Ruddy et al., 2002). Viable organisms can 
present additional problems, especially in patients who have started treatment. Therefore, 
even though culture has thus far been considered the gold standard for TB diagnosis, it still 
lacks the desired accuracy; it has been estimated that no more than 81 percent of the 
confirmed TB cases can be detected by culture (API, 2006).  
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2.3 Tuberculin Skin Test (TST) 
Tuberculin skin testing (TST), also known as the Mantoux test or Heaf test, remains in 
widespread use for both the diagnosis of active TB and the detection of latent TB, and for 
the identification of TB in health care workers, for whom the incidence of TB is higher than 
in the general population (Harries et al., 1997; Barrett et al., 1979) and who require routine 
checkups for accidental acquisition of TB infection and chemoprophylaxis. The TST is a 
delayed type hypersensitivity skin test: an induration develops and is measured 48 to 72 
hours after the intradermal inoculation of purified protein derivatives. It is generally 
accepted that in adults a TST response greater than or equal to a 10-millimeter induration is 
indicative of TB infection; however in children, the gauge differs in different settings. 
Importantly, the TST is still used as an epidemiological tool to screen for TB and to calculate 
the annual risk of TB through data generated by TST surveys. TST surveys are useful for 
detection of TB in communities with low case-detection rates, to assess the effect of HIV 
infection on a TB epidemic, and to better understand the effect of both diseases on children 
(Farhat et al., 2006).  
2.3.1 Limitations of the tuberculin skin test  
Although the TST is inexpensive, easily available, and is the preferred test in most TB-
prevalent settings, it has a number of limitations. The TST is not patient friendly, in that it 
requires two visits to the health facility: the first visit is when the test is administered; and 
the second visit, 2 – 3 days later, is to assess the skin’s reaction. It is estimated that one third 
of the people tested never return after the 48- to 72-hour waiting period to have their tests 
read (ATS, 2000; Lee & Holzman, 2002).  
2.3.2 False positives 
Purified protein derivatives contain more than 200 antigens shared with the BCG vaccine 
and many of the non-TB environmental mycobacteria, which can result in low specificity of 
the TST (Huebner et al., 1993; Dacso 1990; Diel et al., 2009; Pai et al., 2008). This cross-
reactivity results in false-positive reporting for a large percentage of the world's population. 
Some reports indicate that BCG vaccination can present TST false-positive results for up to 
15 years after vaccination (Wang et al., 2002). These variables contribute to the false positive 
results: (1) the strain and dose of BCG inoculated (Wang et al., 2002; Davids et al., 2006); (2) 
the method of vaccine administration (Davids et al., 2006); (3) the time since vaccination 
(Menzies, 2000); (4) the number of BCG scars (Babayigit et al., 2011); and (5) the weight and 
age at the time of vaccination (Newort et al., 2004). If the BCG vaccine was received in 
infancy, the impact on TST results is minimal, especially 10 or more years after vaccination. 
A person’s nutrition at the time of vaccination as well as genetic factors can also have an 
impact on the outcome of the TST results later on (Newport et al., 2004). More frequent, 
more persistent, and larger TST reactions were observed in individuals who had received 
the BCG vaccine later in life, ie, after infancy (Pérez-Then et al., 2007; Farhat et al., 2006). 
Sometimes TST indurations between 5–10 millimeters can still develop for up to 25 years 
after vaccination (Miret-Cuadras et al., 1996). The TST false positive reaction was not 
associated with a family history of tuberculosis, with exposure to cigarette smoke, number 
of household family members, and the presence of respiratory allergic diseases (Babayigit et 
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al., 2011). A number of additional factors can contribute to false-positive results including 
inaccuracy of reading and documenting the results (Mancuso et al., 2008).  
Furthermore, the TST does not distinguish between individuals infected with Mtb, 
vaccinated with BCG, or infected with environmental non-TB mycobacteria— almost one 
third of the people who test positive on the TST do not have a TB infection (American 
Thoracic Society [ATS], 2000; Huebner et al.,1993; von Reyn et al., 2001). Clinically non-TB 
mycobacteria rarely causes TST false-positives in low-prevalence settings of TB infection, 
however it does have an effect on the false-positive results of populations with a high 
prevalence of non-TB mycobacteria (Farhat et al., 2006). This lack of specificity (high rate of 
false-positive) in diagnosing both active and latent TB (WHO, 1995) is considered the TST’s 
major drawback. 
2.3.3 False negatives  
The TST can also produce false-negative readings, and these can be product-related 
(associated with improper storage or handling). The number of tuberculin units inoculated 
and the type of tuberculin can have an effect on TST reactivity (Farhat et al., 2006). The 
sensitivity of the test is affected by the immunomodulation of the skin; the DTH response is 
influenced by illness or immunosuppression, and factors such as HIV infection or a young 
child’s age can result in even lower sensitivity of the test for both latent and active TB 
(Swaminathan et al., 2008; Selwyn et al., 1992; Pesanti, 1994; Madariaga et al., 2007; Moreno 
et al., 2001). 
2.3.4 The boosting effect 
Other disadvantages associated with the TST include the “boosting effect,” a phenomenon 
in which multiple TST administrations over time yield a false positive. The increased 
tuberculin reaction is seen in some individuals when a second skin test is administered 1 
week to 1 year after administration of a first skin test that is nonreactive. This could be 
explained as an anamnestic recall of immune response that occurs in individuals with 
remote exposure to mycobacterial antigens. This phenomenon is a problem for people who 
are regularly screened for TB infection using the TST (for example, health care workers, 
hemodialysis patients, etc.) and become immunized to purified protein derivatives by the 
repeated administrations of the test (Dogan et al., 2005; Cengiz & Seker, 2006). Persistent 
negative TST in latent TB-infected individuals, despite the continued exposure, has been 
reported. It has been shown that this reaction can be attributed to genetic factors. These 
genetic factors not only influence the interaction between humans and Mtb but they can 
affect the outcome of the exposure: exposure but no infection, infection without progression, 
or progression to disease (Stein et al., 2008). Subjectivity and inter-individual variability, in 
the administration and reading of the TST can be added to the disadvantages and resultant 
errors, because it is difficult to administer small amounts of the protein uniformly; that is, 
the amount of purified protein derivatives delivered in the TST may vary, and this affects 
the size of the reaction (Chaparas et al., 1985).  
Further research is needed to determine the best cut-offs for TST sensitivity, the optimal 
time for testing candidates, especially for people that need to be tested periodically (such as 
health care workers), and the cost-effectiveness of the test, given its limitations 
(Khawcharoenporn et al., 2011).  
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2.4 Chest X-ray  
Chest radiography can be a useful tool to confirm TB when combined with a patient’s 
history, physical exam, and laboratory tests in symptomatic and even smear-negative 
patients. Pulmonary TB almost always shows abnormalities on the chest radiograph; the 
pulmonary cavities and lesions are smaller when infected with TB than those caused by 
other chest health problems.  
2.4.1 Disadvantages of chest X-ray 
A chest X-ray cannot alone confirm a TB diagnosis. In many cases (40 percent), the infection 
is not in the lungs; radiography may not detect the early stages of TB disease, because the 
damage to the lungs may not yet be sufficiently marked to be detectable by a chest X-ray. 
Also, scarring in the lungs may be detected if previous TB disease has occurred (even if the 
patient is completely cured), and thus it is difficult to distinguish past cured TB from current 
TB disease.  
2.4.2 Computerized Tomography (CT)  
When both chest X-ray and computerized tomography were used to screen for latent TB in 
pre-transplant patients, abnormal findings were only detected on the chest CT (the chest X-
ray results were normal), which indicates that chest CTs can detect latent TB better than 
chest X-rays (Lyu et al., 2011). Many studies have confirmed that CT has detected 
pulmonary TB cases that were missed by chest radiographs. Furthermore, high resolution 
CT alone, or CT together with the TST and INF-γ release assays, were effective in the 
differentiation between active TB and latent TB (Lee et al., 2010; Boloursaz, 2010). Even in 
sputum smear–negative sittings, high-resolution CT findings, such as tree-in bud 
appearance, lobular consolidation, and large nodules, accurately predicted the risk for 
pulmonary TB with reproducible results (Nakanishi et al., 2009).  
2.5 Nucleic acid amplification test  
The nucleic acid amplification test detects the nucleic acid specific to Mtb using an 
amplification technique (Noordhoek et al., 1995; Kadival et al., 1995; Nagi et al., 2007). 
Nucleic acid amplification is a relatively new assay for TB diagnosis that is available only in 
specialized, advanced laboratories (ATS, 2000). DNA amplification offers a fairly specific 
and sensitive diagnostic method in both pulmonary and extra-pulmonary TB, and most 
studies have shown it to be more sensitive than sputum smear microscopy, but less sensitive 
than microbial culture (Pfyffer, 1999; Magana-Arachchi et al., 2008). The specificity (ruling in 
disease) of the nucleic acid amplification test is high when applied to body fluids (extra-
pulmonary), such as meningitis and pleural TB). 
2.5.1 Limitations of the nucleic acid amplification test  
The sensitivity (ruling out disease) can be compromised especially in respiratory specimens, 
where it can be highly variable and more inconsistent than specific (it is only about 60 
percent effective under optimal conditions). This variability can be explained by the use of 
different cut-off values used in the different studies (Dinnes et al., 2007; Daley & Pai, 2007), 
www.intechopen.com
 
Diagnosis of Mycobacterium tuberculosis 
 
95 
in addition to the sequence variation in both commercial and in-house assays (Whilley et al., 
2008).  
Evaluation of commercial nucleic acid amplification tests in both pulmonary TB and extra-
pulmonary TB indicated that nucleic acid amplification tests have high, consistent specificity 
and positive predictive values in smear-positive patients (Ling et al., 2008; Piersimoni et al., 
2002; Reischl et al., 1998; Caruyvels et al., 1996; Coll et al., 2003; Goessens et al., 2005; 
Miragliotta et al., 2005; Ozkutuk et al., 2006; Guerra et al., 2007; Franco-Alvarez et al., 2006); 
however, in smear-negative cases, when a rapid diagnostic test is needed, the accuracy of 
the test is more modest and variable, and the results may be influenced by patient selection 
and the clinical setting in which the tests are carried out (Brown et al., 1999; Barnes, 1997).  
Similar results were obtained when the clinical impact of the nucleic acid amplification test 
systems were evaluated in low-income countries that have a high burden of TB and HIV. 
The nucleic acid amplification test assays used in these studies had moderate sensitivity and 
high specificity for TB in a predominantly HIV-seropositive population with negative 
sputum-smear (Davis et al., 2011; WHO, 2010).  
Different laboratories report significant variability in the reproduction of this test, which can 
lead to false-positive results (Chedore et al., 2006); this is a major concern because of the 
DNA contamination of assay reagents. Even though nucleic acid amplification test 
techniques can amplify a small amount of genetic material, the sample must still contain a 
certain number of TB bacteria to be effective, and this collection is not always possible, 
particularly with nonpulmonary TB (Haldar et al., 2007). Therefore, it has been suggested 
that nucleic acid amplification tests should be combined with other diagnostic tests (for 
example, tests detecting INF-γ) in order to increase the sensitivity of the test (Dinnes et al., 
2007). Another disadvantage of the nucleic acid amplification test is that the assay cannot 
distinguish dead from viable organisms, so a positive result may indicate active disease 
even though the TB has been cured (Manjunath et al., 1991).  
Although the test itself takes little time to administer, the time required to obtain the results 
is considerable. Laboratories often culture the sample first, to allow the bacteria to multiply 
(which takes a few weeks), before carrying out the nucleic acid amplification test. The 
nucleic acid amplification test method requires some level of technical skill (invasive 
procedures are sometimes necessary to obtain samples), and is prone to cross 
contamination. In order to provide valid results, the nucleic acid amplification test must be 
run in an environment that minimizes and detects cross-contamination and test-appropriate 
controls. Nucleic acid amplification tests can be expensive, and in underdeveloped countries 
where the high-burden TB exists, commercial nucleic acid amplification tests are rarely used 
because of cost and complexity. Although some studies suggest that nucleic acid 
amplification tests are cost-effective in diagnosing TB even in low-income countries (van 
Cleeff et al., 2005; Dowdy et al., 2008), their use has been limited. In-house techniques that 
might be substituted for commercial assays often produce results that can’t be validated 
(Daley et al., 2007). When molecular methods were compared with conventional diagnostic 
procedures, mostly microscopic detection, it was found that the microscopic method on its 
own is better than the molecular method, because of the extra care needed to interpret the 
results (Runa et al., 2011).  
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2.5.2 New approach to the nucleic acid amplification test 
A more recent commercial nucleic acid amplification test (the hyplex TBC test), which meets 
the demand for a low-cost system, has been introduced. The hyplex test is a qualitative 
system for the detection of members of the Mtb complex, and it is based on a multiplex 
polymerase chain reaction followed by reverse hybridization to specific oligonucleotide 
probes and enzyme-linked immunosorbent assay (ELISA) detection. In comparison to other 
commercial nucleic acid amplification test systems, the hyplex TBC shows good specificity 
but lower sensitivity, especially with smear-negative TB specimens; it also gives false-
negative results, which puts it in the same class as the other nucleic acid amplification test 
assays (Hofmann-Thiel et al., 2010).  
These observations indicate that commercial nucleic acid amplification tests cannot replace 
conventional tests and cannot be used alone to confirm TB. Improvement of this technique, 
especially its sensitivity, is required in order for it to be beneficial for the diagnosis of TB in 
low-resource countries where the prevalence of disease is higher than in other parts of the 
world. 
3. New, more specific tests 
3.1 Antibody-based diagnosis assay (TB ELISA) 
Recently, many new serological procedures have been evaluated for diagnosing TB. 
Enzyme-linked immunosorbent assays (ELISA) theoretically represent attractive 
serodiagnostic methods, because they are simple, rapid, inexpensive, and do not require 
much training or sophisticated equipment. Several researchers have tried to develop ELISA 
tests utilizing different antigens, such as culture filtrate, purified extracts of glycolipid, and 
mycobacterial sonication antigens, as well as more specific mycobacterial non-recombinant 
and recombinant antigens of Mtb (Daniel et al., 1986; Escamilla et al., 1996; Laal et al., 1997). 
Tests using such antigens were designed to detect immunoglobulins IgG, IgM, or IgA 
against these TB-specific antigens in whole blood, plasma, or serum of both pulmonary and 
extra-pulmonary TB patients (Imaz et al., 2001; Raja et al., 2002, 2004; Ramalingam et al., 
2002; Zheng et al., 1994; Patil et al., 1996). Antigens from mycobacteria other than Mtb (M. 
habana) were also evaluated for their ability to diagnose extra-pulmonary TB using ELISA, 
and these antigens were found to be effective (Chaturvedi & Gupta 2001). To date, the 38-
kDa antigen is the best candidate for the ELISA technique for diagnosing TB in actively 
infected individuals—but it is not reliable in extra-pulmonary or TB-HIV co-infected 
patients (Abebe et al., 2007). Because the available ELISA tests cannot achieve a high 
sensitivity, these tests are unacceptable as single diagnostic tools for TB detection (Chiang et 
al., 1997; Ravn et al., 2005; Weldingh et al., 2005; Araujo et al., 2004; Raja et al., 2002). The use 
of relatively low pure Mtb antigens has contributed to the low sensitivity of the test. 
Different studies have suggested that a combination of several key antigens (antigen 
cocktail) may result in better sensitivity. These antigens are presumably the specific, 
antigens to detect the latent and early stages of the active infection in both pulmonary TB as 
well as extra-pulmonary TB (Houghton et al., 2002). In order to develop a successful 
serodiagnostic method for TB, several factors must be considered: antigen recognition by 
infected individuals varies depending on the stage of the disease; the heterogeneity of 
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human leukocyte antigen in different populations; bacterial load; and the immunological 
status of the patient (Abebe et al., 2007).  
3.1.1 New approaches to ELISA 
Recently, an ELISA test (lipoarabinomannan [LAM] antigen-detection assay) that uses 
urine as a sample has been developed, standardized, and is commercially available 
(Clearview® TB ELISA) (Boehme et al., 2005; Hamasur et al., 2001; Tessema et al., 2001). 
This test has many advantages: it is non-invasive, patient friendly, simple (dipstick 
prototype form of the test is available), rapid (requires 15 minutes to perform), easy to 
use, and it uses urine, which is a sterile biological fluid that is easier to obtain than 
sputum, which some patients have difficulties producing. Moreover, the test can be used 
with other body fluids, including sputum (Dheda, et al., 2010) cerebral-spinal fluid (Patel 
et al., 2009), and pleural fluid (Dheda K et al., 2009). However, the preliminary data 
indicate that the sensitivity of the urine LAM, although better than sputum microscopy in 
HIV-infected patients (Lawn et al., 2009), is still not adequate to replace mycobacterial 
culture in TB-infected patients, and the diagnostic efficacy is limited and requires further 
study (Gounder et al., 2011). 
A promising, more rapid, and cost-effective form of ELISA has been developed: the 
Immunochromatographic (ICT) Test Kits; these kits detect serum antibodies against Mtb-
specific antigens that are secreted by Mtb during active infection. The high sensitivity, 
specificity, and positive predictive values suggest that these kits are useful and simple 
diagnostic tools, especially for resource-poor diagnostic centers (Kumar et al., 2011). 
3.2 Interferon-Gamma Release Assays (IGRAs) 
Effector T cells of the cell-mediated immune response are normally present as a result of 
recent host encounters with antigen. T effector cells are short-lived and die off when the 
antigen is cleared from the host. Due to the short life of the effector T cells, their continued 
presence indicates that the cellular immune response is fighting a pathogen somewhere in 
the body. Therefore, diagnosis of an acute infection can be made by noting the presence of 
the antigen-specific effector T cells in a patient's blood or serum sample and by measuring 
the release of cytokines by the T effector cells when re-exposed to antigen in vitro. It has 
been shown recently that TB-specific Th1, Th22, and Th17 cells have an essential role in the 
immunity against TB infection; this provides a potential target for diagnosis and therapeutic 
intervention in TB disease (Qiao et al., 2011; Wozniak et al., 2010). 
Th1 cells, which secrete INF-γ, are known to protect the body against the Mtb infection. 
This fact provides a unique way to examine the TB disease for diagnosis, prognosis, and 
treatment monitoring (Flynn et al., 1993; Boom, 1996; Gallegos et al., 2008). The 
production of INF-γ is influenced by many external factors, such as TB infection, and 
internal factors, such as interleukin (IL)-10, IL-12, IL-18, and IL-23 (Yu et al., 2011; Zhang 
J, et al., 2011; Han et al., 2011; Sahiratmadja et al., 2006). In fact some studies have 
suggested that some cytokines such as TNF-alpha, IL-2, IL-12, and IL-17 can be used to 
discriminate between active and latent TB disease (Sutherland et al., 2010; Schauf et al., 
1993); however the exact role of each of these cytokines is not fully understood and needs 
to be investigated further.  
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Different reports have shown that the peripheral-blood mononuclear cells from patients 
infected with TB release INF-γ when exposed to Mtb-specific antigens in vitro (Ravn et al., 
1999; Ulrichs et al., 1998; Lalvani et al., 2001 Mori et al., 2004). Based on these findings, 
different diagnostic assays have been developed to measure INF-γ released by peripheral-
blood mononuclear cells cells in response to Mtb-specific antigens. Two such antigens are 
the early secreted antigenic target 6-kDa (ESAT-6) protein and culture filtrate protein 10-kDa 
(CFP-10) (Andersen et al., 2000; Tully et al., 2005). Both antigens have been shown to be 
important for the growth, survival, and pathogenesis of Mtb (Brodin et al., 2005; Munk et al., 
2001). These proteins are secreted by Mtb in great quantities during the infection or when 
the bacteria are cultured in vitro (Andersen et al., 2000; Behr et al., 1999; Pai et al., 2004). Both 
ESAT-6 and CFP-10 are encoded within the region of deletion 1 (RD1) and are more specific 
to the organism because they are present in Mtb but are not shared with the BCG vaccine or 
with most of the environmental mycobacteria (Goletti et al., 2006; Sorensen et al., 1995; 
Harboe et al., 1996).  
3.2.1 The interferon-gamma release assay tests  
These discoveries have resulted in the development of two promising, blood-based, 
commercially available INF-γ release assay tests that have been approved for clinical use for 
the diagnosis of TB infection, and that use ESAT-6 and CFP-10 antigens: (1) QuantiFERON-
TB Gold (QFT-G), which has been replaced in many parts of the world by a safer and 
simpler test method, QFT-G in-tube assay (QFT-IT) (Cellestis Limited Carnegie, Victoria, 
Australia) in which an additional Mtb-specific antigen TB7.7 is incorporated into the test 
(Syed et al., 2009; Stavri et al., 2009); and (2) T-SPOT.TB assay (Oxford Immunotech, Oxford, 
United Kingdom). Although the two tests share common features, they also have some 
technical distinctions (Richeldi, 2006). The two INF-γ release assays are designed to measure 
INF-γ production (INF-γ release assays) in two different ways, from peripheral-blood 
mononuclear cells of TB patients when exposed in vitro to ESAT-6 and CFP-10 proteins. 
QFT-G measures the quantity of INF-γ secreted by T cells, and T-SPOT.TB assay enumerates 
the number of TB-specific T cells secreting INF-γ after exposure to TB-specific antigens. Both 
of the INF-γ release assays require only a single patient visit, and the test results are 
available within 24 hours (Hill et al., 2004; Richeldi et al., 2004).  
Many studies have shown that the QFT-G test is fairly accurate and has modest sensitivity 
to detect active TB (Kobashi et al., 2006; Kang et al., 2007; Pai et al., 2007). The QFT-G offers 
specificity of up to 97 percent in clinical trials, sensitivity of up to 89 percent, and provides 
clinicians with an accurate, reliable, and convenient TB diagnostic tool (Mori et al., 2004; 
Kobashi et al., 2006).  
QFT-G has been useful for the diagnosis and differentiation between pulmonary TB and 
other pulmonary diseases; however it too has its limitations. Because the results depend on 
the clinical condition of the patients and the presence of immunosuppressive diseases, 
patients with localized lesions of TB infection and the elderly can sometimes get false-
negative results (Kobashi et al., 2008; Kawabe, 2007).  
The T-SPOT.TB test, on the other hand, quantifies the number of the INF-γ-producing TB-
specific cells using a technology known as the Enzyme Linked Immunosorbent Spot 
(ELISPOT) assay, which is widely recognized as the most sensitive technique to measure 
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antigen-specific T cell function. In the T-SPOT.TB assay, recently developed by Lalvani and 
coworkers, individual T cells specific for the two antigens (ESAT-6 and CFP-10) are 
enumerated (Lalvani, Pathan et al., 2001; Lalvani, Nagvenkar et al., 2001). With this technique, 
peripheral-blood mononuclear cells from infected individuals are cultured overnight (16–20 
hours) with ESAT-6 and CFP-10 antigens to allow the release of INF-γ by the sensitized T cells 
(Lalvani & Hill, 1998; Lalvani et al., 1998). A single T cell produces a dark spot, which is the 
footprint of an individual Mtb-specific T cell, and the number of spots is quantified.  
The T-SPOT.TB technique has an estimated pooled specificity of 93 percent and up to 90 
percent sensitivity for patients with culture-confirmed TB from low-incidence countries; its 
sensitivity, therefore, is higher than the TST (Lalvani, Pathan et al., 2001; Lalvani, 
Nagvenkar et al., 2001), and it has a better performance than the TST in detecting active TB 
(Ozekinci et al., 2007). 
In addition, T-SPOT.TB detects specific T cells at frequencies as low as 1 cell per 300,000 
bystander cells (Heeger et al., 2001), making the assay very sensitive for detecting immune 
responses even in immunosuppressed individuals actively or latently infected, in very 
young children, in those on anti-TNF-α treatment, in transplant and renal dialysis patients, 
and in pregnant women (Gebauer et al., 2002; Piana et al., 2007).  
Therefore, although QFT-G has some advantages over T-SPOT.TB; for instance, it is 
relatively easy to perform, requires fewer steps and less-expensive equipment—which 
makes it more suitable for “on-filed” usage in settings with limited resources—it has been 
shown in different reports to be less sensitive than the T-SPOT.TB assay (Adetifa et al., 
2007). It is notable that the INF-γ release assays may vary in different populations 
depending on various factors, including genetic background, disease epidemiology, 
prevalence of HIV infection, exposure to environmental mycobacteria that have similar 
antigens, malnutrition, and other factors (Pai et al., 2004; Dinnes et al., 2007).  
3.2.2 Interferon-gamma release assays: A tool to monitor TB chemotherapy 
The response of INF-γ-producing T-cells in INF-γ release assays might be related to bacterial 
load (Hill et al., 2005); therefore, it could be used as a quantitative surrogate marker to 
monitor TB chemotherapy and drug efficacy during treatment, progression, or relapses 
(Komiya et al., 2011; Takayanagi et al., 2011; Ribeiro et al., 2009). In addition, a strong 
association between the T-SPOT.TB score and the degree of sputum positivity in patients 
has been reported (Oni et al., 2010). 
It has been suggested that INF-γ release assays can provide useful, accurate, and rapid 
support in the diagnosis of extra-pulmonary TB (Lai et al., 2011; Patel et al., 2010; Lai et al., 
2010). Although INF-γ release assays have higher sensitivity and specificity than 
conventional methods, further studies are needed to evaluate their role in diagnosing 
children and extra-pulmonary TB infections, especially in high TB-endemic settings 
(Amdekar et al., 2010).  
3.2.3 A comparison of the interferon-gamma release assays with the tuberculin skin test  
Both INF-γ release assays (QuantiFERON and T-SPOT.TB )are beginning to replace the TST, 
and both assays have been approved recently for clinical use in the United States, Europe, 
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and Japan (FDA, 2005; Lalvani, Pathan, 2001). It has been shown that the INF-γ release 
assays have many advantages over the TSTs in the diagnosis of active as well as latent TB, 
especially in low-TB-endemic countries (Pai et al., 2004; Dinnes et al., 2007; Fukazawa, 2007; 
Kang et al., 2007; Ozekinic et al., 2007; Bartu et al., 2008; (Harada et al., 2008; Kabeer et al., 
2010; Pia et al., 2008; Diel et al., 2009; Park et al., 2009; Toshiyama et al., 2010; Latorre et al., 
2009). Since both assays are specific to Mtb and are not affected by previous exposure to 
environmental mycobacteria or vaccination with BCG, they have greater specificity and 
sensitivity than the TST in the diagnosis of latent TB in adults (Ewer et al., 2003; Shams et al., 
2005; Kang et al., 2005).  
In the majority of studies that compare the performance of INF-γ release assays with TSTs, 
INF-γ release assays seem to be significantly more accurate than TSTs and have poor 
agreement with it (I mean the TST), for the diagnosis of active or latent TB, in both 
immunocompetent or HIV-infected individuals (Rangaka et al., 2007; Mandalakas et al., 
2008; Stephan et al., 2008; Jiang et al., 2009; Cağlayan et al., 2011; Cesur et al., 2010). In fact, 
moderate to poor diagnostic agreement between the different INF-γ release assays tests 
themselves has been observed (Richeldi et al., 2009; Talati et al., 2009; Latorre et al., 2010). 
Nevertheless, determining the accuracy of either one of the INF-γ release assay tests to 
detect latent infections presents a challenge, because there is no gold standard available 
(Newton et al., 2008), and the only criteria that can be used is the patient’s history of 
exposure to the disease (if known). Therefore, the accuracy and reliability of the estimated 
number of the global latent TB cases remains uncertain (Wiker et al., 2010). When INF-γ 
release assays were compared with TSTs in different longitudinal studies, INF-γ release 
assays may have a higher predictive value regarding the development of future TB, and 
unlike the TST, the INF-γ release assays (QFTGIT) results are not affected by gender or age 
of participants (Bakir et al., 2008; Legesse et al., 2011). Nevertheless, the decision to use INF-
γ release assays instead of TSTs is often based on country guidelines and resource and 
logistics considerations (Cattamanchi et al., 2011). 
3.2.4 The indeterminate response of interferon-gamma release assays 
All INF-γ release assays are designed to include mitogen stimulation of tested cells as a 
positive control, along with the different TB-specific antigens used in the tests, to measure 
the ability of the harvested cells to produce INF-γ; when cells from tested individuals fail to 
respond sufficiently to either TB-specific antigens or, more specifically to the used mitogen 
control, the results are considered indeterminate. The indeterminate response can be 
explained by an error in specimen collection and handling or by the performance of the 
assay or T-cell anergy, which result in an inadequate response (Papay et al., 2011; Kobashi et 
al., 2009). 
Among the different forms of the INF-γ release assays, QFT-IT has a lower rate of 
indeterminate results compared with T-Spot.TB, because of the simplicity of the in-tube 
form, which does not require as many steps as T-Spot.TB, and the fact that there is no 
storage of blood. T cells interact with antigens as soon as blood is collected into the QFT 
tubes, minimizing the potential loss of activity during storage of blood specimen.  
Differences in indeterminate results have been observed among the different INF-γ release 
assay tests given to children; with children, both QFT-G and QFT-IT (ELISA-based assays) 
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are significantly more affected by indeterminate results than T-SPOT.TB (ELISPOT-based 
assay) (Bergamini et al., 2009). These indeterminate results can be minimized by applying 
the assays after acute inflammation is resolved; this later application also reduces the cost of 
retesting (Zrinski et al., 2011).  
3.2.5 Interferon-gamma release assays and detection of TB in children 
Uncertainty about the sensitivity of INF-γ release assays to detect TB in children remains an 
issue; the use of INF-γ release assays to detect active and latent TB infection in children, 
seem to perform differently. Some studies have shown that the QFT-IT has a high sensitivity 
and less indeterminate rates in nonimmunosuppressed children of all age groups (from 1 
month to 18 years old) (Zrinski et al., 2011). However, others have shown that both forms of 
QuantiFERON-TB tests (QFT-G and QFT-IT) were less sensitive and can give more 
indeterminate results than T-SPOT.TB in children younger than 4 years old (Bergamini et al., 
2009; Nicol et al., 2009; Takamatsu, 2008).  
It is a priority to detect and contain the disease in this age group. Because young children 
have a higher chance of developing active TB than older children, as a consequence of an 
impaired T-cell response (Lewinsohn et al., 2004), the American Academy of Pediatrics has 
recently recommended that the TST continue to be used to diagnose TB in children younger 
than 5 years old, and that INF-γ release assays be used for children older than 5 years old 
(Starke, 2009; Mazurek et al., 2010). However, because of the high risk in the 5-and-under 
age group, it has been suggested that both tests (QFT and the TST) be used in combination, 
whenever it is possible. This combination of tests would improve the diagnosis of TB, and 
the child would be considered infected if either or both are positive (Debord et al., 2011; 
Pavic et al., 2011). Other studies with children older than five, HIV-infected children, or 
nonimmunosuppressed children, indicated that indeterminate results with QFT-G, QFT-IT, 
or T-SPOT.TB—were undetected or uncommon (Bergamini et al., 2009; Mandalakas et al., 
2008; Tsiouris et al., 2006).  
The variation in the level of cytokines (INF- γ and IL-2) released by cells after stimulation 
with QFT antigens in children, is age dependent; it can identify those children with latent TB 
who are younger than 5 years old from those older than 5 years old (Lighter-Fisher et al., 
2010).  
3.2.6 Interferon-gamma release assays for testing TB in children with cancer 
Both the TST and the INF-γ release assays were used to detect TB in children with cancer 
before their initial chemotherapy. All tests performed suboptimally, and therefore none of 
them can be used individually to confirm or disprove TB infection (Stefan et al., 2010). 
3.2.7 Interferon-gamma release assays and screening for latent TB  
In adult patients, latent TB can be detected more effectively with INF-γ release assays than 
with the TST; QFT-G and QFT-IT can be used for diagnosis and T-SPOT.TB for exclusion 
(Chang & Leung 2010). However, in some settings, both tests are used to screen for TB 
(Torres Costa et al., 2011; Katsenos et al., 2011). 
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Although INF-γ release assays are affected by cellular immune statutes and age, they 
demonstrate low agreement with the TST and perform better in detecting latent TB in adult 
patients (Santín Cerezales 2011; Zhao et al., 2011). Both of the INF-γ release assays (T-
SPOT.TB and QFT) require only a single patient visit, and the test results are available 
within 24 hours (Hill et al., 2004; Richeldi et al., 2004).  
The Centers for Disease Control and Prevention, USA, recommend that INF-γ release assays 
can replace the TST (single screening strategy) in all settings (Mazurek et al., 2005). 
However, recent UK TB guidelines advise screening for latent TB using the TST, followed by 
INF-γ release assays if the TST is positive (dual screening) (Leyten et al., 2007; Sauzullo et 
al., 2011; Dosanjh et al., 2008;148: Ritz et al., 2011). The dual screening strategy has been 
reported to be more cost-effective than the single screening strategy (INF-γ release assay or 
TST alone) for screening latent TB; however this conclusion and the interpretation of results 
is relative to the prevalence of TB in the setting as well as the length of contact with the 
infection (Pooran et al., 2010).  
3.2.8 Drawbacks of interferon-gamma release assays 
One limitation of the INF-γ release assays is that they are inconsistent in detecting TB in HIV 
patients. Some reports indicate that they are not the best tools for diagnosing TB among 
HIV-infected individuals with advanced immunodeficiency diseases, because of low 
sensitivity resulting from the low T-cell count (Chen et al., 2011). However, other studies 
reported that the sensitivity of the T-SPOT.TB assay in detecting TB in active HIV disease 
may be not highly impaired by advanced immunosuppression (Oni et al., 2010). 
Another limitation of INF-γ release assays is their inability to distinguish active from past-
treated TB infections (Kim et al., 2011; (Kim et al., 2010). The role of INF-γ release assays to 
distinguish between latent TB and active TB and their predictive ability of the progression of 
latent TB to active TB infection needs to be studied further, especially in high-burden 
settings (Dheda et al., 2009). Therefore, although INF-γ release assays have been approved 
in many countries to diagnose latent TB, especially in adults, this test still has little clinical 
value in the diagnosis of active TB (Dominguez et al., 2009). Nevertheless, growing evidence 
supports the idea that recruiting Mtb-specific T cells in active TB from fluids at the “local” 
sites of infection, such as pleural effusion (Wilkinson et al., 2005; Barnes et al., 1993; Barnes 
et al., 1989), cerebrospinal fluid (Thomas et al., 2008), ascites (Wilkinson et al., 2005), 
pericardial fluid (Biglino et al., 2008), and bronchoalveolar lavage (BAL) (Jafari et al., 2006; 
Jafari et al., 2009) is more effective than blood, in the diagnosis of extra-pulmonary TB. In 
this way the INF-γ release assays are looking at the “local “ site of infection rather than 
“systemic” Mtb-specific immune response in blood, which may only provide background 
information about effector memory T-cells in active TB. This provides a promising approach 
to distinguish active TB from latent TB in routine clinical practice (Jafari et al., 2009). 
The cut-off values currently recommended by the manufacturers are being disputed in 
some studies (Soysal et al., 2008). Consideration of new (low) cut-off values for both T-
SPOT.TB and QFT, which may improve the assays’ sensitivity, are now recommended, 
especially in intermediate- and high-endemic areas of TB and HIV (Soysal et al., 2008; 
Kanunfre et al., 2008; Legesse et al., 2010). The relative complexity of the INF-γ release 
assays can result in technical errors at many levels, resulting from insufficient cells, 
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reduced cells activated due to prolonged transport or storage of blood, improper handling 
of specimens, the presence of INF-γ antibodies, and the incorrect addition of mutagen. 
Any of these technical problems can contribute to the invalidity and inaccuracy (unusual 
INF-γ measurements) of the test results, adding to its potential disadvantages 
(Kampmann et al., 2005; Powell et al., 2011). 
The level of complexity mentioned above in addition to the requirement for special 
equipment, skilled laboratory personnel, and the high cost of the INF-γ release assays are 
among the limitations of the assays, which should be strongly considered, especially in low-
resources settings. INF-γ release assays are recommended for use as a confirmation tool 
when a patient with negative TST is suspected of having TB, or to exclude a positive TST 
result from BCG vaccination (Sun et al., 2010). 
3.2.9 Interferon-gamma release assays and detection of TB in patients with  
immune-mediated inflammatory diseases  
Studies involving immune-mediated inflammatory diseases (such as psoriasis, rheumatoid 
arthritis, etc.) indicated that INF-γ release assays are superior to the TST for detecting latent 
TB in both endemic and non-endemic areas (Ponce de Leon et al., 2005; Ponce de Leon et al., 
2008; Sellam et al., 2007; Murakami et al., 2009; de Andrade et al., 2011). 
Since most of the information on the performance of INF-γ release assays have been 
gathered from studies done in developed countries, it is important that further research on 
adults and children be done in developing countries where TB is endemic. These studies 
should include the presence of additional factors that have been reported to cause false 
negative results as high as 35.5 percent; these factors include HIV infection, malnutrition, 
impaired immune status, age, and the different ethnic backgrounds of patients (Pai et al., 
2006; Menzies et al., 2007; Im et al., 1991; Landis & Koch, 1977; Legesse et al., 2010; Legesse 
et al., 2011 Apr 9;11:89).  
Despite the progress that has been made in studying the use of INF-γ release assays, 
additional research is still required to study further the limitations of the assays and the 
ways to overcome them to improve the best utility of the tests in diagnosing and controlling 
TB (Lalvani & Pareek 2010; Mazurek et al., 2010). 
4. Conclusions 
Despite the continued research to identify the key Mtb antigens and biomarkers for 
developing the ideal diagnostic test, there is not yet a rapid, reliable, and economical 
method to diagnose both active and latent TB. The importance of diagnosing latent TB is 
often overshadowed in many parts of the world; however, it is key to controlling the spread 
of infection. In the last few years, new tests have been developed based on significant 
advances in understanding the genomic and immunology of Mtb. The new tests include the 
nucleic acid amplification test, QuantiFERON-TB and T-SPOT.TB, which have the 
advantages of higher specificity and sensitivity than the conventional tests—important for 
physicians so that they can avoid the inappropriate treatment of false-positive vaccinated 
individuals. Yet these new tests have disadvantages as well, including cost, training, and 
complexity. None of the available microbiological or immunological tests alone can 
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accurately confirm the TB infection, while waiting for the culture results which can take 
weeks. Given the global burden of this disease, and its potential to spread rapidly, the 
importance of developing a novel assay or improving the existing methods for TB detection, 
active and latent, has never been greater. 
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